Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study

Fetal Diagnosis and Therapy

Volumn 13, Issue 6, 1998, Pages 367-371

  Brajenović Milić, Bojana ^a   Tišlarić, Dubravka ^b   Bačić, Josip ^c   Paravić, Jadranka ^a   Slivar, Anatelo ^d   Kapovic, Miljenko ^a   Košec, Vesna ^b   Ristic, Smiljana ^a   Rajhvajn, Branko ^e  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c Public Health Center   (Croatia)

^d Clinical Hospital   (Croatia)

^e Center of Gynecology 'Supernova'   (Croatia)

Author keywords

Alpha fetoprotein; Down's syndrome screening; Free human chorionic; Gonadotropin

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT;

ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CROATIA; DOWN SYNDROME; ENCEPHALOCELE; ENZYME IMMUNOASSAY; FEMALE; GASTROSCHISIS; HUMAN; IMMUNORADIOMETRIC ASSAY; NEURAL TUBE DEFECT; NORMAL HUMAN; PRENATAL SCREENING; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; TRISOMY 21;

ADULT; ALPHA-FETOPROTEINS; AMNIOCENTESIS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CROATIA; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FETAL DISEASES; GESTATIONAL AGE; HUMANS; KARYOTYPING; MATERNAL AGE; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES;

EID: 0032415271     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020871     Document Type: Article

References (20)

1. Wald NJ, Cukle HS, Densem, JW, Nunchahal K, Royston P, Dhard T, Hadow JE, Knight GJ, Palomaki GE, Canik JA: Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-887.
2. Spencer K: Antenatal screening for Down's syndrome. BMJ 1992;305:769.
3. Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, Romero K, Larsen JW: Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990;163:1248-1253.
4. Wald NJ, Kennard A, Hackshaw AK: First trimester serum screening for Down's syndrome. Prenat Diagn 1995;15:1224-1240.
5. Markatz IR, Nitowsky HM, Macri JN, Johnson WE: An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol 1984;148: 886-894.
6. Spencer K, Carpenter P: Prenatal screening for Down's syndrome using free beta human chorionic gonadotropin: Results of a prospective study. BMJ 1993;307:764-768.
7. EUROCAT Working Group: EUROCAT Report 6. Surveillance of congenital anomalies in Europe 1980-1992. Brussels, Institute of Hygiene and Epidemiology, 1995.
8. Brajenović-Milić, Ristić, Kapović, Mojsović A, Medica I, Modrušan-Mozetič Z: Incidence of Down's syndrome in the municipality of Rijeka and Istrian region. Coll Antropol 1996; 20(suppl):1-5.
9. Cuckle HS, Wald NJ, Thompson SG: Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.
10. Huang T, Watt HC, Wald NJ: The effect of differences in the distribution of maternal age in England and Wales on the performance of prenatal screening for Down's syndrome. Prenat Diagn 1997;17:615-621.
11. Wenstrom KD, Desai R, Owen J, Du Bard MB, Boots L: Comparison of multiple marker screening with amniocentesis for the detection of fetal aneuploidy in women ≥ 35 years old. Am J Obstet Gynecol 1995;173:1287-1192.
12. Spencer K, Macri JN, Anderson RW, et al: Dual analyte immunoassay in neural tube defect and Down's syndrome screening: Results of a multicentre clinical trial. Ann Clin Biochem 1993;30:394-401.
13. Macri JN, Spencer K, Garver K, et al: Maternal serum free beta hCG screening: Results of studies including 480 cases of Down's syndrome. Prenat Diagn 1994;14:97-103.
14. Haddow JE, Palomaki GE: Similarities in woman's decision-making in the US and UK during prenatal screening for Down's syndrome. Prenat Diagn 1996;16:1161-1162.
15. Lam YH, Ghosh A, Tang MHY, Tang LCH, Lee CP, Sin SY, Ho PKH: Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. Prenat Diagn 1998; 18:585-589.
16. UK Collaborative Study: Maternal serum alpha-fetoprotein measurements in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977;I:1323-1332.
17. Ferguson-Smith MA: The reduction of anencephalic and spina bifida births by maternal serum alpha-fetoprotein screening. Br Med Bull 1983;39:365.
18. Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung YK, Jick H: Predictive values relative risk, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: New epidemiologic data. Am J Obstet Gynecol 1989;161:291-297.
19. Burton BK: Unexplained elevated maternal serum alpha-fetoprotein and adverse perinatal outcome; in Elias S, Simpson JL (eds): Maternal Serum Screening. New York, Churchill-Livingstone, pp 109-119.
20. Van der Veen WJ, Beekhuis JR, Conel MC, Mantingh A, De Walle HEK, De Wolf BTHM: A demographic approach to the assessment of Down's syndrome screening performance. Prenat Diagn 1997;17:717-724.